Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MASP2 | O00187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078157 | 0.86 | F2 (0.47) | F2MEN1KMT2AL3MBTL1APOBEC3A | |
| SCHEMBL6078680 | 0.86 | MASP2 (0.51) | F2MASP2 | |
| SCHEMBL6077876 | 0.82 | F2 (0.56) | F2MEN1KMT2AL3MBTL1APOBEC3A | |
| SCHEMBL6077859 | 0.82 | F2 (0.56) | F2MEN1KMT2AL3MBTL1APOBEC3A | |
| SCHEMBL6078817 | 0.80 | F2 (0.54) | F2MEN1KMT2AL3MBTL1APOBEC3A | |
| SCHEMBL6077693 | 0.78 | F2 (0.53) | F2MEN1KMT2AL3MBTL1APOBEC3A | |
| SCHEMBL6078951 | 0.78 | F2 (0.49) | F2MEN1KMT2AAPOBEC3AAPOBEC3G | |
| SCHEMBL6077685 | 0.76 | F2 (0.53) | F2MEN1KMT2AL3MBTL1APOBEC3A | |
| SCHEMBL6078722 | 0.75 | F2 (0.44) | F2MEN1KMT2AL3MBTL1MASP2 | |
| SCHEMBL6078688 | 0.72 | MASP2 (0.53) | F2MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | F2 1/4885MEN1 494/4885KMT2A 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.